



Atty. Dkt. No. 087147-0494

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: INADA et al.
Title: PHARMACEUTICAL COMPOSITION FOR
ANGIOTENSIN II-MEDIATED DISEASES
Appl. No.: 10/781,263
Filing Date: 2/19/2004
Examiner: Deborah C. Lambkin
Art Unit: 1626
Conf. No.: 3131

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b)(4), before the mailing date of the first Office Action after the filing of a Request for Continued Examination.

RELEVANCE OF EACH DOCUMENT

Any document listed on the attached PTO/SB/08 was cited as being relevant during the prosecution of one of two corresponding European applications. Copies of the relevant European Search Reports and European Communications are attached setting forth the portion of each document considered relevant by the examiner. An English-language abstract of the foreign-language documents has been provided where readily available. The absence of a translation or an English-language counterpart document does not relieve the PTO from its duty to consider any submitted document (37 CFR §1.98 and MPEP §609).


Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit card payment form being unsigned, providing incorrect information resulting in a rejected credit card transaction, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,


Date September 7, 2006

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

By  (45,943)
SEAN A. PASSINO
Stephen B. Maebius
Attorney for Applicant
Registration No. 35,264
FOR

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: September 7, 2006 <i>(use as many sheets as necessary)</i>				Complete if Known	
Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number		10/781,263 2/19/2004 Yoshiyuki Inada 1626 Deborah C. Lambkin 087147-0494			
Sheet	1	of	2		



U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	B1	EP	0 461 039	B1	Hoechst Marion Roussel	12/11/1991		A
	B2	WO	95 21609	A	Ciba-Geigy AG	08/17/1995		
	B3	EP	0 533 058	B1	Hoechst AG	03/24/1993		A
	B4	AU	657478	B	Roussel-UCLAF	12/12/1991		
	B5	AU	659485	B	Hoechst AG0	03/18/1993		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
	B6	BERKOW, The Merck Manual of Diagnosis and Therapy, 14 th Ed., 1982, Merck Sharp & Dome Research Laboratories, p. 2366.		
	B7	BORHANI et al., "The multicenter isradipine/diuretic atherosclerosis study: A study of the antiatherogenic properties of isradipine in hypertensive patients," J. Cardiovasc. Pharm., vol. 18, no. Suppl. 3, 1991, pp. S15-S19, XP008037314.		
	B8	HAUSTEIN, "Heutiger Stand und Trends der Sklerodermie-Behandlung," Hautarzt, vol. 43, 1992, pp. 409-416, XP008037316.		
	B9	TOLLEFSON, "Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia," Biol. Psychiatry, vol. 27, 1990, pp. 1133-1142, XP008037307.		
	B10	DE ANGELIS, "Effect of calcium antagonists in the elevated plus-maze test of anxiety," European Journal of Pharmacology," vol. 183, no. 5, 1990, pp. 1974-1975, XP008037308.		
	B11	CHAMONTIN et al., "Effect d'un inhibiteur calcique, la nicardipine, sur la secretion de l'aldosterone au cours de l'hyperaldosteronisme primaire," Arch. Mal. Coeur, vol. 82, 1989, pp. 1237-1240, XP008037317.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: September 7, 2006 (use as many sheets as necessary)		Application Number	10/781,263
		Filing Date	2/19/2004
		First Named Inventor	Yoshiyuki Inada
		Group Art Unit	1626
		Examiner Name	Deborah C. Lambkin
Sheet	2	of	2
		Attorney Docket Number	087147-0494



NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	B12	BEATTY et al., "Elevation of intraocular pressure by calcium channel blockers," Arch. Ophthalmol., vol. 102, 1984, pp. 1072-1076, XP008037319.	
	B13	JOHNSON, "Calcium channel blockade and resistant bipolar depression," Irish J. Psychol. Med., vol. 8, 1991, pp. 50-51, XP008037311.	
	B14	WITZMANN, "Effect of spironolactone on intraocular pressure in glaucoma patients," Klinische Monatsblätter für Augenheilkunde, vol. 176, no. 3, 1980. pp. 445-446, XP008050793.	
	B15	REYNOLDS, Martindale The Extra Pharmacopoeia Thirtieth Edition, 1993, The Pharmaceutical Press, p. 806-832.	
	B16	PECZON et al., "Diuretic drugs in glaucoma," Am. J. Ophthalm., vol. 66, no. 4, 1968, pp. 680-683, XP002067602.	
	B17	FUMIHIKO OKADA, "Depression after treatment with thiazide diuretics for hypertension," Am. J. Psychiatry, vol. 142, no. 9, 1985, pp. 1101-1102, XP008037312.	
	B18	GRIFFING et al., "Reversal of diuretic-induced secondary hyperaldosteronism and hypokalemia by Enalapril: a new angiotensin-converting enzyme inhibitor," Metabolism, vol. 32, no. 7, 1983, pp. 711-716, XP008037313.	
	B19	MATSUMOTO et al., "Effects of Aldosterone Receptor Antagonist and Angiotensin II Type I Receptor Blocker on Cardiac Transcriptional Factors and mRNA Expression in Rats With Myocardial Infarction," Circ. J., 2004, 68, pp. 376-382.	
	B20	INADA et al., "Antihypertensive Effects of a Highly Potent and long-Acting Angiotensin II Subtype-1 Receptor Antagonist...in Various Hypertensive Rats," J. Pharm. Exp. Ther., vol. 268, no. 3, March 1994, pp. 1540-1547, XP008014592.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.